Phase II Study of the Combination of Palbociclib and Cetuximab in KRAS/NRAS/BRAF Wild-type Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Cetuximab (Primary) ; Palbociclib (Primary)
- Indications Colon cancer
- Focus Therapeutic Use
- 27 Mar 2018 Planned End Date changed from 1 Mar 2024 to 13 Jul 2023.
- 27 Mar 2018 Planned primary completion date changed from 1 Mar 2023 to 13 Jul 2020.
- 19 Mar 2018 Status changed from not yet recruiting to recruiting.